DCXR monoclonal antibody (M03), clone 6A6
- Known as:
- DCXR mab (anti-) (M03), clonality 6A6
- Catalog number:
- H00051181-M03
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Abno
- Gene target:
- DCXR monoclonal antibody (M03) clone 6A6
Related genes to: DCXR monoclonal antibody (M03), clone 6A6
- Gene:
- CENPJ NIH gene
- Name:
- centromere protein J
- Previous symbol:
- MCPH6
- Synonyms:
- CPAP, BM032, LAP, LIP1, Sas-4, SASS4, SCKL4
- Chromosome:
- 13q12.12-q12.13
- Locus Type:
- gene with protein product
- Date approved:
- 2002-02-15
- Date modifiied:
- 2018-02-13
- Gene:
- CENPN NIH gene
- Name:
- centromere protein N
- Previous symbol:
- C16orf60
- Synonyms:
- FLJ13607, FLJ22660, BM039
- Chromosome:
- 16q23.2
- Locus Type:
- gene with protein product
- Date approved:
- 2006-02-20
- Date modifiied:
- 2015-08-24
- Gene:
- DCXR NIH gene
- Name:
- dicarbonyl and L-xylulose reductase
- Previous symbol:
- -
- Synonyms:
- KIDCR, DCR, SDR20C1
- Chromosome:
- 17q25.3
- Locus Type:
- gene with protein product
- Date approved:
- 2002-07-25
- Date modifiied:
- 2018-07-10
- Gene:
- DONSON NIH gene
- Name:
- downstream neighbor of SON
- Previous symbol:
- C21orf60
- Synonyms:
- B17, C2TA, DKFZP434M035
- Chromosome:
- 21q22.11
- Locus Type:
- gene with protein product
- Date approved:
- 2000-02-18
- Date modifiied:
- 2017-03-30
- Gene:
- EAPP NIH gene
- Name:
- E2F associated phosphoprotein
- Previous symbol:
- C14orf11
- Synonyms:
- BM036, FLJ20578
- Chromosome:
- 14q13.1
- Locus Type:
- gene with protein product
- Date approved:
- 2002-11-18
- Date modifiied:
- 2016-02-26
Related products to: DCXR monoclonal antibody (M03), clone 6A6
Related articles to: DCXR monoclonal antibody (M03), clone 6A6
- Gestational diabetes mellitus (GDM) poses significant health risks, yet the causal genetic and epigenetic mechanisms linking glycolipid metabolism dysregulation to GDM remain elusive. This study aimed to identify key causal genes and regulatory pathways by integrating multi-omics data with large-scale genetic association studies. - Source: PubMed
Publication date: 2026/05/20
Lin XiaoxiaoZheng JingjingQin NingningLi Yimei - Recent evidence has established a significant link between N4 acetylcytidine (ac4C) mRNA modification, mediated by N Acetyltransferase 10 (NAT10), and bone metabolism. Nonetheless, the precise role and regulatory targets of NAT10, along with its associated ac4C modification in human bone formation, remain inadequately characterized. This study employed bioinformatics analysis of transcriptomic datasets from primary osteoblasts of individuals with high versus low bone mineral density (BMD), alongside a curated set of ac4C-modified genes, to identify key differentially expressed genes (DEGs) regulated by this pathway within an osteogenic context. Overall, eleven key NAT10/ac4C-associated DEGs linked to BMD status were identified: CFD, CTSF, DCXR, FADS1, GOLIM4, IMPA2, MLEC, NCLN, NT5DC2, PTGFRN, and VASP. Notably, FADS1, NT5DC2, and PTGFRN emerged as crucial ac4C-modified genes across three machine learning models. Furthermore, the tri-gene signature (FADS1/NT5DC2/PTGFRN) showed excellent diagnostic performance in distinguishing different BMD statuses. In vitro validation using MC3T3-E1 osteoblastic cells revealed that the knockdown of NAT10 via lentiviral delivery markedly impaired cell proliferation and osteogenic differentiation. This impairment was evidenced by the results of the CCK-8 proliferation assay, alkaline phosphatase staining, and Alizarin Red staining. Additionally, qRT PCR analysis demonstrated a significant downregulation of FADS1 and NT5DC2 expression subsequent to NAT10 knockdown. These findings underscore the role of NAT10-mediated ac4C modification as a pivotal regulator of osteoblast activity and gene expression programs associated with BMD. This research offers novel insights into the regulation of bone metabolism and proposes potential diagnostic markers and therapeutic targets for osteoporosis. - Source: PubMed
Tang YWang QDong WJiang GLei MHu XWu YJiang WHao JHu Z - The World Health Organisation (WHO) recommends digital chest radiography (dCXR) with computer-aided detection (CAD) for tuberculosis (TB) screening of individuals >15 years of age. - Source: PubMed
Publication date: 2026/04/30
Nyangu SarahMulenga HumphreyMendelsohn Simon CPerumal TahliaTameris MicheleMoloantoa TumeloMalherbe Stephanus TNoor FirdowsShenje JustinTredoux NicoletteKany Luabeya Angelique KanyMaruri FernandaPanchia RavindreHlongwane KhuthadzoStanley Kimvan der Heijden Yuri FHadley KateMartinson NeilDheda KeertanLeslie AlFourie BernardWalzl GerhardScriba Thomas JSterling Timothy RHatherill Mark - The World Health Organization recommends community-based tuberculosis active case finding using digital chest radiography with computer-aided detection (dCXR/CAD) and/or molecular diagnostics, but clinical and economic outcomes are unclear. - Source: PubMed
Deleger Julie NKhatami S NazaninJones MichelleJalali Mohammad SPaltiel A DavidWong Emily BFlorance GradyFreedberg Kenneth AWood RobinHorsburgh C RobertReddy Krishna P - BACKGROUND: Migraine and Meniere’s disease (MD) show high clinical comorbidity, shared symptoms such as vertigo and overlapping mechanisms like neurogenic inflammation suggest common pathophysiology. However, the core immunogenetic drivers underlying this comorbidity, particularly at cellular resolution, remain uncharacterized. METHODS: We integrated cross-trait genetic analyses using summary statistics from large genome-wide association study (GWAS) and single-cell expression quantitative trait locus (sc-eQTL), followed by Bayesian colocalization. Candidate genes were validated with independent single-cell RNA sequencing (scRNA-seq) and their therapeutic potential was assessed via drug repurposing and Phenome-wide association studies (PheWAS). RESULTS: We identified a significant genetic correlation (rg = 0.226) and 4 high-confidence shared prioritized genes (cell division cycle 42 [CDC42], dicarbonyl and L-xylulose reductase [DCXR], GTP binding protein 4 [GTPBP4], sterol-c5-desaturase [SC5D]). Single-cell analyses confirmed their cell-type-specific dysregulation. Drug target interrogation identified existing pharmacological agents interacting with these genes, including Lorlatinib for CDC42. PheWAS highlighted distinct safety profiles for each target, informing future therapeutic development priorities. CONCLUSIONS: This study reveals a shared immunogenetic basis between migraine and MD at single-cell resolution, providing novel targets and a translational roadmap for therapeutic development. CLINICAL TRIAL: Not applicable. - Source: PubMed
Publication date: 2026/04/18
Hu XiaoWang YangYu Si-JiePan Chun-YaLiang Bing-YuJiang Shang-ShangChen Shan-WenHan Yan-Xun